Enfusion Financial Statements From 2010 to 2025

ENFN Stock  USD 11.07  0.11  1.00%   
Enfusion financial statements provide useful quarterly and yearly information to potential Enfusion investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enfusion financial statements helps investors assess Enfusion's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enfusion's valuation are summarized below:
Gross Profit
131.1 M
Profit Margin
0.017
Market Capitalization
B
Enterprise Value Revenue
5.183
Revenue
195.2 M
We have found one hundred twenty available fundamental signals for Enfusion, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Enfusion's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 17th of January 2025, Market Cap is likely to grow to about 1.8 B. Also, Enterprise Value is likely to grow to about 1.9 B

Enfusion Total Revenue

126.54 Million

Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 2 M or Depreciation And Amortization of 12.1 M, as well as many indicators such as Price To Sales Ratio of 5.36, Dividend Yield of 0.0034 or PTB Ratio of 15.07. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Enfusion Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets88.2 M125.3 M51.5 M
Slightly volatile
Short and Long Term Debt Total13.2 M13.9 M27 M
Pretty Stable
Other Current Liabilities13.8 M13.2 M3.6 M
Slightly volatile
Total Current Liabilities14.2 M23.4 M10.9 M
Slightly volatile
Other Liabilities411.7 K484.2 K543.7 K
Slightly volatile
Property Plant And Equipment Net39.4 M37.5 M13.4 M
Slightly volatile
Current Deferred Revenue2.1 M2.2 M5.6 M
Slightly volatile
Accounts Payable1.6 M2.5 M968.8 K
Slightly volatile
Cash40.1 M40.9 M19.8 M
Slightly volatile
Non Current Assets Total47.2 M45 M16 M
Slightly volatile
Non Currrent Assets Other7.9 M7.5 M2.6 M
Slightly volatile
Other Assets1.091.151.2 M
Very volatile
Long Term Debt67.9 M110.5 M52.3 M
Slightly volatile
Cash And Short Term Investments40.1 M40.9 M19.8 M
Slightly volatile
Net Receivables20.5 M32.3 M14.2 M
Slightly volatile
Common Stock Shares Outstanding111.4 M148.8 M111.5 M
Very volatile
Liabilities And Stockholders Equity88.2 M125.3 M51.5 M
Slightly volatile
Non Current Liabilities Total9.6 M10.1 M101.6 M
Slightly volatile
Inventory7.4 MM1.7 M
Slightly volatile
Other Current AssetsM7.1 M3.6 M
Slightly volatile
Total Liabilities26.9 M28.3 M112.4 M
Slightly volatile
Property Plant And Equipment Gross59.6 M56.7 M18.8 M
Slightly volatile
Short and Long Term Debt1.5 M2.9 M1.1 M
Slightly volatile
Total Current Assets66.3 M80.3 M37.1 M
Slightly volatile
Non Current Liabilities Other411.7 K484.2 K543.7 K
Slightly volatile
Net Working Capital52.1 M57 M26.2 M
Slightly volatile
Short Term Debt4.6 M4.9 M2.3 M
Slightly volatile
Property Plant Equipment12 M18.1 MM
Slightly volatile
Deferred Long Term Liabilities1.3 M1.5 M1.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity30.7 M34.6 M37.7 M
Slightly volatile
Common Stock Total Equity91.2 K102.6 K111.9 K
Slightly volatile
Capital Surpluse195.4 M219.8 M239.7 M
Slightly volatile

Enfusion Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision867 K1.6 M672.3 K
Slightly volatile
Depreciation And Amortization12.1 M11.5 M3.6 M
Slightly volatile
Interest ExpenseM1.9 M1.2 M
Slightly volatile
Selling General Administrative74 M74.3 M39.7 M
Slightly volatile
Selling And Marketing Expenses26.1 M23.5 M14.7 M
Slightly volatile
Total Revenue126.5 M200.7 M89.6 M
Slightly volatile
Gross Profit88.1 M134.4 M62.6 M
Slightly volatile
Other Operating Expenses182.8 M187 M100.5 M
Slightly volatile
Research Development44.2 M22.9 M19.1 M
Slightly volatile
Cost Of Revenue38.5 M66.3 M27 M
Slightly volatile
Total Operating Expenses144.4 M120.7 M73.4 M
Slightly volatile
Reconciled Depreciation4.8 M9.4 M2.9 M
Slightly volatile
Income Tax Expense2.7 M2.6 M902.3 K
Slightly volatile

Enfusion Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow75.5 M71.9 M21.9 M
Slightly volatile
Depreciation12.1 M11.5 M3.6 M
Slightly volatile
Other Non Cash Items10.1 M9.6 M2.1 M
Slightly volatile
Capital Expenditures7.7 M11.1 M5.9 M
Slightly volatile
Issuance Of Capital Stock14.8 M15.6 M61.5 M
Very volatile
End Period Cash Flow40.1 M40.9 M19.8 M
Slightly volatile
Change To Netincome28.8 M30.4 M25.5 M
Slightly volatile
Change To Liabilities6.3 MM1.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.365.6427.5786
Slightly volatile
Dividend Yield0.00340.00270.004
Slightly volatile
Days Sales Outstanding46.7852.8355.7174
Very volatile
Stock Based Compensation To Revenue0.04670.04911.9649
Slightly volatile
Capex To Depreciation1.061.112.931
Slightly volatile
EV To Sales5.235.527.7922
Slightly volatile
Inventory Turnover6.176.947.57
Slightly volatile
Days Of Inventory On Hand44.7142.5811.3695
Slightly volatile
Payables Turnover32.7829.9734.772
Slightly volatile
Sales General And Administrative To Revenue0.460.330.3896
Slightly volatile
Average Inventory2.9 M2.7 M733.6 K
Slightly volatile
Research And Ddevelopement To Revenue0.09750.10.1613
Pretty Stable
Capex To Revenue0.07010.06370.0705
Slightly volatile
Cash Per Share0.370.360.2183
Slightly volatile
Days Payables Outstanding11.8212.6111.5047
Slightly volatile
Current Ratio3.973.13.118
Slightly volatile
Receivables Turnover6.887.156.5308
Very volatile
Graham Number1.061.111.9563
Very volatile
Capex Per Share0.06540.09870.0578
Slightly volatile
Revenue Per Share1.061.780.888
Slightly volatile
Interest Debt Per Share0.320.20.2655
Very volatile
Debt To Assets0.150.160.938
Slightly volatile
Short Term Coverage Ratios3.844.0426.8302
Slightly volatile
Operating Cycle54.3552.8359.1475
Pretty Stable
Days Of Payables Outstanding11.8212.6111.5047
Slightly volatile
Ebt Per Ebit0.750.870.9273
Slightly volatile
Quick Ratio3.913.13.0923
Slightly volatile
Net Income Per E B T0.990.60.9212
Slightly volatile
Cash Ratio2.461.581.6218
Slightly volatile
Cash Conversion Cycle42.5440.2247.6434
Pretty Stable
Days Of Inventory Outstanding44.7142.5811.3695
Slightly volatile
Days Of Sales Outstanding46.7852.8355.7174
Very volatile
Cash Flow Coverage Ratios0.831.490.7811
Slightly volatile
Fixed Asset Turnover8.696.158.9212
Slightly volatile
Debt Ratio0.150.160.938
Slightly volatile
Cash Flow To Debt Ratio0.831.490.7811
Slightly volatile
Price Sales Ratio5.365.6427.5786
Slightly volatile
Asset Turnover1.861.842.1906
Slightly volatile
Gross Profit Margin0.770.66970.7168
Slightly volatile

Enfusion Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B983.9 M1.9 B
Slightly volatile
Enterprise Value1.9 B960.7 M1.9 B
Slightly volatile

Enfusion Fundamental Market Drivers

Forward Price Earnings48.5437
Cash And Short Term Investments35.6 M

Enfusion Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as revenue or net income, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 M2.1 M
Total Revenue200.7 M126.5 M
Cost Of Revenue66.3 M38.5 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.33  0.46 
Research And Ddevelopement To Revenue 0.10  0.10 
Capex To Revenue 0.06  0.07 
Revenue Per Share 1.78  1.06 
Ebit Per Revenue 0.08  0.08 

Pair Trading with Enfusion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.

Moving together with Enfusion Stock

  0.65DJCO Daily Journal CorpPairCorr
  0.82AI C3 Ai IncPairCorr
  0.84AZ A2Z Smart TechnologiesPairCorr
  0.67BL BlacklinePairCorr

Moving against Enfusion Stock

  0.82VERB VERB TECHNOLOGY PANYPairCorr
  0.81VTEX VTEXPairCorr
  0.54ILLRW Triller Group Symbol ChangePairCorr
  0.36QH QuhuoPairCorr
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.04
Revenue Per Share
2.155
Quarterly Revenue Growth
0.154
Return On Assets
0.0592
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.